Form 4: Phreesia Director Executes Pre-Planned Share Sale and Option Exercises

Phreesia Director Michael Weintraub sold 10,000 common shares at $30 and exercised options for 10,000 shares under a Rule 10b5-1 plan.

Summary

• Director Michael Weintraub engaged in a series of transactions on August 25, 2025, pursuant to a Rule 10b5-1 trading plan adopted on January 6, 2025.
• Sold 10,000 shares of Phreesia Common Stock at a price of $30 per share. Following this sale, direct beneficial ownership was 158,229 shares.
• Exercised options to acquire 3,113 shares of Common Stock at an exercise price of $8.03 per share. Following this acquisition, direct beneficial ownership was 161,342 shares.
• Exercised options to acquire 6,887 shares of Common Stock at an exercise price of $4.71 per share. Following this acquisition, direct beneficial ownership was 165,116 shares.
• The total number of shares acquired through option exercises was 10,000 (3,113 + 6,887).
• Indirect beneficial ownership includes 30,795 shares through the Michael Weintraub 2023 Qualified Annuity Trust and 6,703 shares through the Weintraub Family 2017 Irrevocable Trust.
• Remaining directly held derivative securities include 10,540 stock options with an exercise price of $8.03, expiring March 26, 2029.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, the execution under a Rule 10b5-1 plan mitigates this concern, indicating pre-planned financial management rather than a reaction to adverse company news. The profitable exercise of options also reflects positively on the insider's past compensation and the stock's performance relative to strike prices.

Positives

• The sale of shares at $30 indicates a profitable transaction for the insider, as option exercise prices were significantly lower ($8.03 and $4.71).
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a systematic approach to managing personal holdings rather than a reaction to new, non-public information.

Negatives

• A director selling shares, even under a 10b5-1 plan, could be perceived by some investors as a lack of conviction in the company's near-term growth prospects, although this is often for personal financial planning and diversification.

Risks

• No specific company-related risks are mentioned in this Form 4 filing, which primarily reports insider transactions. The general risk associated with insider sales is a potential negative signal, but this is mitigated by the Rule 10b5-1 plan.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance, as it primarily reports insider transactions.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common across all industries as executives manage personal finances and diversify holdings. For Phreesia, a healthcare technology company, these transactions reflect an individual director's financial planning rather than a direct commentary on industry trends or competitive positioning.

Comparison to Industry Standards

• This filing reports standard insider transactions (option exercises and share sales) executed under a Rule 10b5-1 plan, which is a common and accepted practice for corporate insiders across all industries to mitigate accusations of trading on material non-public information.
• There are no specific company or project results to compare against industry benchmarks in this type of filing.

Related Party Transactions

• Michael Weintraub indirectly holds 30,795 shares through the Michael Weintraub 2023 Qualified Annuity Trust and 6,703 shares through the Weintraub Family 2017 Irrevocable Trust, which are considered related party holdings.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even under a 10b5-1 plan, might be interpreted by some as a slight negative signal, but the pre-planned nature generally reduces this concern. The profitable option exercises demonstrate value creation for the insider.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this insider transaction filing.

Next Steps

• The filing does not specify any future actions or milestones for the company, as it pertains to an individual's stock transactions.

Key Dates

Recommendation

This Form 4 filing reports routine insider transactions (option exercises and a pre-planned sale) by a director. The transactions were executed under a Rule 10b5-1 plan, indicating they are part of a systematic financial management strategy rather than a reaction to new material information. While a sale by a director could be a minor negative signal, the pre-planned nature and the profitable exercise of options do not provide sufficient new information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting further operational or strategic updates from the company.

Keywords

Phreesia, PHR, Michael Weintraub, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1, Director Transaction, Healthcare Technology